Universal Ibogaine Announces Results of the Annual Meeting of Shareholders

Core Points - Universal Ibogaine Inc. held its annual meeting of shareholders on September 4, 2025, where significant decisions regarding the company's governance and compensation were made [1][2]. Shareholder Meeting Results - A total of 129,390,665 shares, representing 41.4% of the 312,858,516 outstanding common shares, were voted at the meeting [3]. - The election results for the Board of Directors showed that nine nominees were elected, with varying levels of support, including: - Constantine Buzunis: 90.9% in favor - Ken Cranwill: 90.9% in favor - James Duncan: 44.3% in favor - Peter Demos Ginakes: 91.0% in favor - Eric Hrimech: 44.3% in favor - Nick Karos: 44.0% in favor - Nia Killebrew: 44.3% in favor - Peter Vlahos: 90.6% in favor - Tony Wagner: 44.3% in favor [3][4]. Compensation and Equity Plans - The Board approved the granting of 13,500,000 Restricted Share Units (RSUs), including 6,000,000 RSUs to CEO Nick Karos, with vesting occurring one year after the grant date [2]. - The company's 2025 Employee Equity Incentives Plan (EICP) and 2024 Stock Option Plan (SOP) were not re-approved, as they did not meet the required 50% minimum shareholder approval [4][5]. Company Overview - Universal Ibogaine Inc. is focused on transforming addiction treatment through medicalized ibogaine, with plans for a Canadian clinical trial targeting opioid use disorders [6]. - The company is also developing a holistic addiction treatment protocol at its Kelburn Recovery Centre, aimed at improving the lives of individuals and families affected by addiction [6].